Introduction
============

There is a growing body of evidence from human imaging studies that chronic cocaine users exhibit altered white matter (Lim et al., [@B17], [@B18]; Moeller et al., [@B22]; Ma et al., [@B19]; Lane et al., [@B15]). Diffusion tensor imaging (DTI) studies have shown reduced fractional anisotropy (FA), which suggests altered white matter integrity in the corpus callosum (Moeller et al., [@B22]; Ma et al., [@B19]) and frontal white matter tracts (Lim et al., [@B17]) in cocaine dependent subjects compared to non-cocaine using controls. These differences in white matter integrity appear to have functional significance, as they are related to behavioral measures of impulsivity and decision making (Lim et al., [@B18]; Lane et al., [@B15]), as well as treatment outcome (Xu et al., [@B37]). Further support for an association between white matter changes and cocaine abuse is provided by a post-mortem study showing that cocaine abusers had reduced expression of the transcript encoding proteolipid protein-1 (PLP1) compared to matched control subjects (Kristiansen et al., [@B13]).

A question that remains from these studies is whether cocaine is causal in the association between white matter impairment and cocaine abuse. A recent DTI study demonstrated that continuous exposure to cocaine administered via osmotic mini pumps resulted in significantly lower FA in the corpus callosum compared to rats administered saline (Narayana et al., [@B24]). In addition, significantly lower myelin basic protein (MBP) in the corpus callosum of rats was confirmed histologically after continuous cocaine exposure relative to controls (Narayana et al., [@B24]). This study supports cocaine as a potential causal agent in the white matter changes seen in cocaine abusers. However, the precise mechanisms of action by which cocaine to alters white matter remain unknown.

Myelin is an essential component of white matter (Nave, [@B26]). Several proteins have been shown to be important for myelin production, including PLP1, MBP, and the transcription factor SRY-related HMG-box-10 (SOX10). PLP1 and MBP are the predominant proteins of the myelin sheath produced by oligodendrocytes (Harauz et al., [@B8]). SOX10 is an essential transcription factor regulating oligodendrocyte differentiation. Mice deficient in *Sox10* develop precursor oligodendrocytes, but differentiation to mature oligodentrocytes is disrupted (Stolt et al., [@B32]), and recent studies have shown that SOX10 is required for the survival of myelinating oligodendrocytes (Takada et al., [@B34]). There is evidence that the production of these proteins is affected by chromatin associated changes since an age related decline of histone deacetylation and methylation in the chromatin of oligodenrocytes in the corpus callosum has been observed, an effect that could at least partially explain the age related reduction in the ability of the brain to repair myelin (Shen et al., [@B31]). Other drugs of abuse have been shown to have chromatin associated effects; repeated treatment with opioids has been shown to be associated with alterations of DNA methylation (Nielsen et al., [@B29], [@B28]). However, no study to date has examined epigenetic mechanisms associated with myelin production during withdrawal from self-administered cocaine. This is an exploratory study designed to determine if DNA methylation changes in several genes whose products play a role in oligodendrocyte differentiation and myelin formation occur in response to cocaine treatment. Specifically, the purpose of this study was to determine chronic effects of cocaine administration followed by 1 or 30 days of abstinence on DNA methylation of three genes (*Mbp*,*Plp1*, and *Sox10*) that encode MBP, PLP, and SOX10, respectively, proteins associated with myelin formation.

Materials and Methods
=====================

Ethics statement
----------------

All experiments were carried out in accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals (National Research Council, Institute of Laboratory Animal Research, Commission on Life Sciences, [@B25]) and with the approval of the Institutional Animal Care and Use Committee at University of Texas Medical Branch (Protocol \#88-03-039).

Animals
-------

Adult male Sprague-Dawley rats (*n* = 19; Harlan Sprague-Dawley Inc., Indianapolis, IN, USA), weighing 275--300 g at the start of the experiment were used. Upon arrival, rats were handled and given 4--5 days to acclimate to their environment. All animals were individually housed in a climate-controlled vivarium with a 12-h light/dark cycle (lights on: 7:00 a.m., lights off: 7:00 p.m.) and given access to food (standard rat chow) and water *ad libitum* throughout the phases of the study (i.e., self-administration, forced abstinence, cue reactivity test).

Self-administration procedures and tissue dissection
----------------------------------------------------

Standard self-administration procedures were employed (Nic Dhonnchadha et al., [@B27]; Cunningham et al., [@B4]). Implantations of intravenous catheters with back mounts were performed under anesthesia with a cocktail containing 8.6 mg/kg of xylazine, 1.5 mg/kg of acepromazine, and 43 mg/kg of ketamine in bacteriostatic saline (0.9% NaCl). Small incisions were made in the right posterior neck and just below the left shoulder blade to expose the right jugular vein and to insert the catheter base, respectively. A subcutaneous burrow was made between the two incisions, and the catheter apparatus was pulled through this burrow. The catheter was composed of Silastic^®^tubing (Dow Corning, Midland, Michigan, MI, USA) connected to a bent 22-gage metal cannula encased within a plastic screw connector (Plastics One, Roanoke, VA, USA) at one end and affixed with a small ball of aquarium sealant 3.5 cm from the other end. The distal end of the catheter was inserted into the jugular vein and pushed down until flush with the ball of aquarium sealant, terminating outside the right atrium. The catheter was secured to the vein with sutures (braided silk non-absorbable 4.0) on both sides of the aquarium sealant ball. The incision was then sutured (nylon non-absorbable 4.0). The cannula base was encased with dental acrylic and a small mesh circle (3 cm × 3 cm; Polypro mesh 500 μm) affixed to the bottom, which was pulled thru the small incision in the back. The remaining opening was then sutured (nylon non-absorbable 4.0). Control rats were underwent sham surgery; rats were anesthetized and their jugular vein was exposed, but a catheter was not implanted (Nic Dhonnchadha et al., [@B27]; Cunningham et al., [@B4]).

Catheter patency was maintained by daily flushing with a solution of 0.1 mL bacteriostatic saline containing heparin sodium (10 U/mL, American Pharmaceutical Partners, IL, USA), streptokinase (0.67 mg/mL, Sigma, St. Louis, MO, USA), and ticarcillin disodium (66.67 mg/mL, Research Products International, Mt. Prospect, IL, USA) after each self-administration session. Proper catheter functioning was verified periodically throughout the experiment by intravenous (i.v.) administration of 10 mg/mL methohexital sodium (Monarch Pharmaceuticals Inc., Bristol, TN, USA), a dose sufficient to briefly anesthetize the animal only when administered i.v. The rats were allowed at least 5 days of recovery after surgery before initiation of self-administration training.

Standard operant chambers (Med-Associates, St. Albans, VT, USA) housed in ventilated sound-attenuating cubicles (Med-Associates) with fans to mask outside noise were utilized for self-administration. Each chamber was equipped with two retractable response levers, a stimulus light above each response lever, and a house light opposite the levers. Infusions were delivered by a syringe within a motor-driven infusion pump (Med-Associates) located outside the chamber. The infusion pumps were connected to liquid swivels (Instech, Plymouth Meeting, PA, USA) which were fastened to the catheters via polyethylene 20 tubing encased inside a metal spring leash (Plastics One). Cocaine (dissolved in 0.9% saline; National Institute on Drug Abuse) or sham self-administration training consisted of 14 consecutive daily 3 h sessions (starting at 9:00 a.m.). Rats were trained to press the active lever to obtain a cocaine infusion (0.75 mg/kg/0.1 mL, i.v.) while each sham rat was placed in the operant chamber daily. Animals were not food-restricted or food-trained prior to commencement of cocaine self-administration and no drug-priming infusions were given during training. Scheduled completions on the active lever resulted in simultaneous activation of the house light and cue light, followed 1 s later by activation of the infusion pump. The 0.1 mL cocaine infusion was delivered over a 6 s period, after which the cue light and pump were inactivated simultaneously. The house light remained illuminated for a 20 s timeout period, during which lever presses had no scheduled consequences. Responses on the inactive lever also had no scheduled consequences. Animals were initially trained on a fixed ratio (FR) 1 schedule of cocaine reinforcement until they met a criterion of seven infusions/h for three consecutive days (with the additional criterion of \<10% variation in the total number of infusions received) and were moved to an FR 5 schedule of reinforcement for the training phase (14 days total).

At the end of the self-administration phase, the cocaine-trained rats were divided into two groups, 1 or 30 days of forced abstinence, matched for their mean drug intake during the self-administration phase. Each sham rat was randomly assigned to either 1 or 30 days of forced abstinence. The rats were returned to their home cages for the duration of the forced abstinence period. Thus, the design of the experiment resulted in the following groups designated by period of forced abstinence: sham rats with 1 day (*n* = 3) or 30 days (*n* = 4) of forced abstinence and cocaine self-administration rats with 1 day (*n* = 6) or 30 days (*n* = 6) of forced abstinence. On the designated day of withdrawal, rats were placed into the self-administration chambers for 60 min and the stimulus complex previously paired with cocaine infusions (lights and motor pump) were presented contingent on a FR 1 schedule of reinforcement. Lever presses in the absence of drug reinforcement were recorded. Immediately following the test, rats were anesthetized with chloral hydrate (400 mg/kg, i.p.), sacrificed and the brains were dissected on ice. Brain tissue from the corpus callosum was frozen in liquid nitrogen and stored at −80°C. DNA was isolated from the brain tissue using the Gentra Purgene DNA isolation method (Qiagen, Valencia, CA, USA) according to the manufacturer's protocol.

Primer design and pcr amplification
-----------------------------------

As reported previously (Nielsen et al., [@B29], [@B28]), possible methylation patterns and bisulfite-altered nucleotides were designed using the Methyl Primer Express 1.0 software (ABI). Predicted bisulfite-treated and untreated sequences were exported to Vector NTI Advance 11 (Invitrogen, Carlsbad, CA, USA). Forward and reverse primers were designed with Methyl Primer Express 1.0 (Life Technologies Corp, Carlsbad, CA, USA) or with Vector NTI Advance 11, and synthesized (Midland Reagent Co., Midland, TX, USA). Regions in the promoters of each gene were amplified with the primers and conditions listed in Table [1](#T1){ref-type="table"}.

###### 

**Primers used for the amplification and sequencing of the bisulfate-treated DNA**.

  Gene      Primer pair                                     Primer sequence                   MgSO~4~ (mM)   Annealing temperature (°C)
  --------- ----------------------------------------------- --------------------------------- -------------- ----------------------------
  *Mbp*     M-RATMBP-3F                                     5′-TTATTTTTTGTTGGGTTTAG-3′        2              54
            M-RATMBP-3R                                     5′-ACATAATCCACCCCAAATAT-3′                       
            M-RATMBP-4F                                     5′-TATAGTAGATTTAAAGAATAATTGG-3′   2              45
            M-RATMBP-4R                                     5′-ATAATACCATCACATCCAAA-3′                       
            M-RATMBP-6F                                     5′-GAGTTTTAGATTATTTAAGAAGAT-3′    2              45
            M-RATMBP-6R                                     5′-ACCATAATAACTAACCCAAT-3′                       
  *Plp1*    M-RATPLP1-5F                                    5′-TGTAGGAGAAGAGGATAAAG-3′        2              54
            M-RATPLP1-5R                                    5′-CCATCCTATATACATTTTCCA-3′                      
            M-RATPLP1-3F                                    5′-ATATAAATTTTAGAGTATGT-3′        2              45
            M-RATPLP1-3R                                    5′-TACTAAACACCAAAATTTCA-3′                       
            M-RATPLP1-4F[^a^](#tfn1){ref-type="table-fn"}   5′-TTTGTATTAGTAGGATGTGG-3′                       
            M-RATPLP1-4R[^a^](#tfn1){ref-type="table-fn"}   5′-TACTAAACACCAAAATTTCAC-3′                      
  *Sox10*   M-RATSox10-3F                                   5′-GGTTTAGGGTTTTGTTTGGTTA-3′      2              60
            M-RATSox10-3R                                   5′-CCCTTTTCTACCCTTCAAAAC-3′                      

*^a^Primers used for the sequencing of the PCR product of the amplification with primers. M-RATPPL1-3F and M-RATPPL1-3R*.

Analysis of the *Mbp* promoter region
-------------------------------------

Three sets of DNA primers were used to assay CpG sites around the transcription start site (TSS) for DNA methylation levels of the *Mbp* gene promoter region. The TSS is based on the sequence of the RefSeq gene NM_030990 and is located at chrX: 124,488,627--124,503,639. Nucleotide numbering of the *Mbp* promoter region is relative to the location of the A of the translation start codon ATG of *Mbp* with the TSS is located at −77. Primers M-RATMBP-4F and M-RATMBP-4R (Table [1](#T1){ref-type="table"}) amplified the promoter region of *Mbp* from −193 to +10. This amplicon was used to evaluate the −138, −123, −111, −101, −58, and −55 CpG sites. Primers M-RATMBP-6F and M-RATMBP-6R amplified the region from −54 to +264 and evaluated the −16, +28, +33, +76, +107, +126, +130, +141, +155, +163, +186, and +191 sites. Primers M-RATMBP-3F and M-RATMBP-3R amplified the DNA from +570 to +886 and evaluated the +606, +624, +646, +693, +708, +794, and +838 CpG sites. Sequencing was performed in both directions using the amplification primers. The CpG sites located between the 6F/6R and the 3F/3R amplicons (+330, +341, +347, +369, +404, +529, +549, and +554) were not evaluated.

Analysis of the *Plp1* promoter region
--------------------------------------

DNA methylation levels of specific CpG sites in the *Plp1* promoter region were determined in a similar manner to that which was done for *Mbp*. The *Mbp* TSS is based on the sequence of the RefSeq gene NM_030990 located at chrX: 124,488,627--124,503,639, and is located at −122 relative to the A of the ATG translation start codon. Relatively few CpG sites are located upstream of the TSS of the *Plp1* gene. The closest CpG site upstream of the *Plp1* gene is located 342 nucleotides from the TSS at −464. The first six CpG sites downstream of the TSS are to be found at −51, +64, +453, +517, +538, 579, and+ 603 nucleotides. Two amplicons were designed to cover these six CpG sites. The first amplicon was used to assess the −51 and +64 CpG sites using primers M-RATPLP1-5F and M-RATPLP1-5R (Table [1](#T1){ref-type="table"}), which amplified the region from −148 to +238. Sequencing was performed in both directions using these primers. The second amplicon examined the +453, +517, +538, 579, and +603 CpG sites using primers M-RATPLP1-3F and M-RATPLP1-3R, which amplified the region of +398 to +747. Sequencing was done in both directions using the internal primers M-RATPLP1-4F and M-RATPLP1-4R.

Analysis of the Sox10 promoter region
-------------------------------------

Two genomic forms of the *Sox10* gene are annotated in GenBank. The upstream TSS form (NM_019193.1) of Sox10 has five exons and the downstream TSS form (NM_019193) has four exons, with the translation start codon located in the second and third exon, respectively. Both these forms of *Sox10* have similar counterparts in the mouse genome (uc007wsv.1 and NM_011437.1). We analyzed the DNA methylation of CpG sites in the upstream promoter region of the *Sox10* gene corresponding to NM_019193.1. The TSS of NM_019193.1 is at chr7: 117,149,939, which is located 2654 nucleotides upstream of the A of the translation start codon. The CpG sites of the upstream TSS of *Sox10* are designated relative to their location from NM_019193.1 TSS, which is designated as +1. The region immediately upstream of the downstream TSS (NM_019193) is not annotated in GenBank. We attempted to sequence this region, but were unable to obtain readable sequence data. Therefore, we were unable to analyze the region surrounding the *Sox10* downstream TSS for DNA methylation levels. Primers M-RATSOX10-3F and M-RATSOX10-3R were used to amplified the *Sox10* upstream promoter region from −272 to +90. Using this amplicon we were able to evaluate the −189, −172, −142, −93, −78, −62, −49 CpG sites. The next CpG site is located 42 nucleotides past the TSS (not evaluated in this study). Methylation data was obtained only from sequencing with the forward primer.

Determination of percent methylated cytosine
--------------------------------------------

Percent cytosine methylation was determined as previously described (Nielsen et al., [@B29]). Briefly, genomic DNA (300 ng) was treated with sodium bisulfite using the EZ-96 DNA Methylation Kit D5004 (Zymo Research, Orange, CA, USA) and amplified (Nielsen et al., [@B29]). DNA was amplified with the primer sets listed in Table [1](#T1){ref-type="table"}. Amplification was performed with 1 μL bisulfite-treated DNA, 1 μM of each primer, 250 μM each of dATP, dCTP, dGTP, and TTP, 50 mM KCl, 4 mM MgCl~2~, 0.625 units AmpliTaq Gold^®^(Applied Biosystems), and 10 mM Tris-HCl (pH 8.3) in 25 μL. Amplification consisted of 5 min at 95°C, 40 cycles of 15 s at 95°C, 15 s at the appropriate annealing temperature, and 30 s at 72°C, followed by a final elongation step at 72°C for 7 min. Purified DNA fragments were sequenced at GENEWIZ, Inc. (South Plainfield, NJ, USA) on an ABI 3730 XL sequencer (Applied Biosystems). Trace files (.ab1) were analyzed using the ESME version 3.2.1 software from Epigenomics AG (Berlin, Germany; Lewin et al., [@B16]). The percent methylation calls by the ESME were reviewed by two independent researchers who visually inspected all the methylation calls using the associated electropherograms generated by the ESME software.

Global DNA methylation
----------------------

Percent of cytosine methylation was determined in duplicate using the Methylamp Global DNA Methylation Quantification Ultra Kit (Epigentek Group Inc., Brooklyn, NY, USA) according to manufacturer's recommendations. Briefly, 200 ng DNA was immobilized to each well, which had been coated with a DNA affinity compound. The methylated fraction of the rat DNA was quantitated using a 5-methylcytosine monoclonal antibody in an ELISA-like reaction. The levels of methylated DNA were determined using an internal standard curve of OD intensity at 450 nm on a VICTOR X5 2030 Multilabel plate reader (PerkinElmer, Waltham, MA, USA).

Statistical analysis
--------------------

The total cocaine intake across the 14 days of self-administration for the rats assigned to 1 and 30 days of forced abstinence was analyzed using the Student's *t*-test (two-tailed). Global methylation was determined for each sample in duplicate. Comparisons of global methylation were made using the Student's *t*-test (two-tailed). For the determination of percent methylation at each CpG site, DNA methylation was quantified for *Mbp* and*Plp1* in each direction separately to control for sequencing and PCR artifacts. The mean of the forward and reverse values were calculated for each CpG site of *Mbp* and *Plp1* for each sample. Data was obtained only in the forward direction for the analysis of the CpGs in the promoter region of *Sox10*. We performed a repeated measures analysis of variance to determine if the pattern of mean methylation levels across each gene was significantly different between cocaine and sham controls in either the 1 or 30 days of forced abstinence. A two-tailed *t*-test was performed using these mean values to examine differences between groups at each CpG site. Individual results were evaluated for significance at *p* ≤ 0.05. Data for the individual CpG sites is reported as point-wise or experiment-wise significance levels. To determine experiment-wise significance levels, a Bonferroni correction was applied.

Results
=======

Cocaine self-administration
---------------------------

Rats (*n* = 19) readily acquired cocaine self-administration (0.75 mg/kg/0.1 mL infusion) in daily 3-h sessions to stability (i.e., seven infusions/h on an FR 5 schedule for at least three sessions) and displayed \<10% variation in the number of infusions received (i.e., cocaine intake) by training day 14 of the self-administration phase. Total cocaine intake across the 14 days of self-administration for the rats assigned to 1 day (346.5 ± 21.3 mg/kg) and 30 days of forced abstinence (291.1 ± 34.1 mg/kg) were not statistically different (*p* = 0.204).

CpG DNA methylation in the *Mbp* gene promoter region
-----------------------------------------------------

The methylation of DNA at 24 CpG sites in the *Mbp* gene promoter region was quantitated in the corpus callosum of rats from the four treatment groups. The DNA methylation pattern of these 24 *Mbp* CpG sites combined was evaluated for differences between groups (Figures [1](#F1){ref-type="fig"}A,B). There was no significant difference in the pattern of mean DNA methylation at the 24 *Mbp* CpG sites seen at either 1 or 30 days of forced abstinence following cocaine self-administration versus the respective sham controls after adjusting for multiple testing.

![**Mean CpG dinucleotide methylation levels in the promoter region of the genes coding for the major myelin proteins*Mbp* and*Plp1*, and the transcription factor *Sox10* in cocaine-treated and control rats**. **(A)** *Mbp* methylation in the 1 day abstinence groups. **(B)** *Mbp* methylation in the 30 day abstinence groups. **(C)** *Plp1* methylation in the 1 day abstinence groups. **(D)**. *Plp1* methylation in the 30 day abstinence groups. **(E)** *Sox10* methylation in the 1 day abstinence groups. −62 CpG site: Sham = 61.7%, cocaine = 46.17%, point-wise *p* = 0.047; experiment-wise *p* = 0.022, point-wise *p* = 0.003. **(F)** *Sox10* methylation in the 30 day abstinence groups. −189 CpG site: Sham = 54.3%, cocaine = 19.0%; point-wise *p* = 0.036: −142 CpG site: Sham = 64.3%, cocaine = 25.4%; point-wise *p* = 0.030: −93 CpG site: Sham = 85.7%, cocaine = 52.0%; point-wise *p* = 0.047: −62 CpG site: Sham = 74.3%, cocaine = 40.0%. point-wise *p* = 0.019. \**p* \< 0.05. Error bars represent SEM.](fpsyt-03-00060-g001){#F1}

CpG DNA methylation in the *Plp1* gene promoter region
------------------------------------------------------

The methylation of DNA at seven CpG sites in the *PIp1* promoter region was quantitated in the corpus callosum of rats from the four treatment groups. The DNA methylation pattern of the combined CpG sites of *Plp1* was assessed for differences between groups (Figures [1](#F1){ref-type="fig"}C,D). There was no significant difference in the pattern of mean DNA methylation of these seven *Plp1* CpG sites seen at either 1 or 30 days of forced abstinence from cocaine self-administration versus the respective sham controls after adjusting for multiple testing.

CpG DNA methylation in the *Sox10* gene promoter region
-------------------------------------------------------

The methylation of DNA at seven CpG sites in the *Sox10* promoter region was quantitated in the corpus callosum of rats from the four treatment groups (Figures [1](#F1){ref-type="fig"}E,F). At these seven *Sox10* CpG sites, the pattern of mean DNA methylation was assessed. On day 1 of forced abstinence a trend was observed for a decrease in the mean DNA methylation pattern in the cocaine self-administered rats compared with the sham controls (*p* = 0.06, Figure [1](#F1){ref-type="fig"}E). A significantly different mean DNA methylation pattern in corpus callosum was observed in rats following 30 days of forced abstinence from cocaine self-administration relative to respective sham controls (experiment-wise *p* \< 0.001, Figure [1](#F1){ref-type="fig"}F). The mean level of methylation of the seven sites combined was 44% lower in rats exposed to 30 days of forced abstinence (38.2%) relative to sham control rats (68.5%). The difference in mean level of methylation between the cocaine and sham groups was significantly higher at 30 days relative to 1 day of forced abstinence (experiment-wise *p* \< 0.001). In addition, we found the 30-day sham control rats expressed a different mean DNA methylation pattern relative to the 1-day sham control rats. In the sham control rats, the mean level of methylation was 33% higher in rats exposed to 30 days of forced abstinence (68.5%) relative to 1 day of forced abstinence (51.4%; *p* = 0.016). In the cocaine self-administration rats, the mean level of methylation was not significantly different between the rats exposed to 1 day (40.7%) or 30 days (38.2%) of forced abstinence.

Since differences were found between the DNA methylation patterns of the *Sox10* promoter region, the individual CpG sites were assessed for differences in methylation levels between rats in the self-administration and sham control conditions exposed to either 1 or 30 days of forced abstinence. On day 1 of forced abstinence, the −62 CpG site was hypermethylated in the forced abstinence versus sham controls. The methylation level of the −62 CpG was 46.17% in the 1 day of forced abstinence compared to 61.7% in the respective sham group (experiment-wise *p* = 0.022, point-wise *p* = 0.003; Figure [1](#F1){ref-type="fig"}E). In contrast, the −189, −142, −93, and −62 CpG sites were hypomethylated at 30 days of forced abstinence versus sham controls (Figure [1](#F1){ref-type="fig"}F). The methylation level of the −189 site was 19.0 ± 2.8% in the 30 days of forced abstinence group versus 54.3 ± 17.3% in the respective sham group (point-wise *p* = 0.036), 25.4 ± 2.7 versus 64.3 ± 18.2% for the −142 CpG site (point-wise *p* = 0.30), 85.7 ± 12.4 versus 52.0 ± 6.4% for the −93 site (point-wise *p* = 0.047), and 40.0 ± 4.5 versus 74.3 ± 10.2% (point-wise *p* = 0.019) for the −62 site.

There was no correlation between the total cocaine intake and DNA methylation at any CpG site for the three genes studied under each condition (data not shown).

Global DNA methylation
----------------------

Analysis of global DNA methylation was performed on DNA from the corpus callosum from rats to assess if any of our results may be due to a change in overall DNA methylation in our sample. No difference in global DNA methylation levels were found between 1 day of forced abstinence (7.7 ± 0.8%) and the respective sham controls (6.1 ± 0.5%), or between 30 days of forced abstinence (6.3 ± 0.5%) and sham control (6.3 ± 0.4%) groups.

Discussion
==========

The overall finding of this study is that forced abstinence from cocaine self-administration in rats is associated with differential changes in DNA methylation of the *Sox10* gene in the corpus callosum. In particular, significant hypomethylation of the *Sox10* gene emerged at 30 days of forced abstinence from cocaine self-administration.

This study was initiated to determine whether forced abstinence from cocaine self-administration was associated with changes in DNA methylation in several myelin genes in white matter, a question which was driven by the consistent findings of altered white matter in cocaine dependent subjects as measured by DTI (Moeller et al., [@B22], [@B23]; Lim et al., [@B18]; Ma et al., [@B19]; Lane et al., [@B15]), white matter volume differences in cocaine dependent subjects (Bartzokis et al., [@B2]), and the association between white matter integrity and better treatment outcome (Xu et al., [@B38]). Similar decreases in white matter integrity have been demonstrated in rats exposed to continuous subcutaneous administration of cocaine via osmotic mini pump (40 mg/kg/day cocaine for 28 days); this study also identified a concomitant decrease in MBP (Narayana et al., [@B24]). In the present study, no changes in DNA methylation were observed in either the *Mbp* or *Plp1* promoter regions following withdrawal from self-administration of cocaine, which might have been expected given the previous observations. However, these two protocols of cocaine administration result in very different pharmacokinetic and pharmacodynamic profiles, and it will be important to establish a comprehensive profile of gene changes in corpus callosum, which could contribute to loss of white matter integrity following cocaine self-administration.

Oligodendrocytes wrap around and insulate neurons to increase the propagation of neuronal action potentials. The oligodendrocyte wraps around central nervous system (CNS) neurons to form the myelin sheath, which is primarily composed of *Mbp* and proteolipid protein (PLP/DM20; lipophilin). Oligodendrocyte maturation proceeds from the differentiation of neural stem cells into immature oligodendrocytes, which subsequently form mature myelinating oligodendrocytes. The initial differentiation is determined, in part, by the oligodendrocyte-specific transcription factor Sox10, which drives oligodendrocyte fate selection and maturation in concert with other transcription factors (Wegner, [@B36]; Gokhan et al., [@B6]).

In one study of patients with glioblastoma, hypermethylation of two specific CpG sites in the *Sox10* gene were found to be associated with reduced gene expression and shorter overall survival (Etcheverry et al., [@B5]), consistent with other studies showing that the presence of oligodendroglial differentiation in glioblastoma patients is associated with longer survival (Salvati et al., [@B30]). In our study, hypermethylation of *Sox10* was observed in the 30 day abstinent sham group compared to the 1 day of abstinence sham group. The difference between the two groups appears to be due to an increase in methylation in the sham group between 1 day of abstinence and 30 days of abstinence, with no increase in methylation between 1 and 30 days of abstinence in the cocaine group. One possible explanation for this difference is that cocaine administration blocked the increase in *Sox10* methylation seen over time in rodents during normal maturation. Previous studies have shown that DNA methylation in the brain changes with age in rodents (reviewed in Takasugi, [@B35]). This would be consistent with human imaging studies showing an inverted U shaped curve for the relationship between white matter integrity as measured by FA on DTI and age (Hasan et al., [@B9]).

Our results show that the overall level of methylation of the *Sox10* gene promoter region was reduced in the corpus callosum after 30 days of abstinence from cocaine compared to levels found after 1 day abstinence from cocaine. The hypermethylation of *Sox10* appears to have occurred by the first day of abstinence in the cocaine self-administered rats, although this was only a trend statistically. This hypomethylation may be in response to cessation of cocaine treatment or to oligodendrocyte damage. Hypomethylation of specific CpG sites in the *Sox10* promoter region in the corpus callosum in response to cocaine treatment could alter the expression of *Sox10* and contribute to altered white matter in cocaine dependence. Alternatively, cocaine hypomethylation of *Sox10* may result in aberrant gene expression that could lead to neurotoxicity and a decrease in white matter integrity. Cocaine has been reported to increase DNA methylation of the promoter region of other genes. Increased DNA methylation of the promoter region of the *Cdkl5* gene in the striatum in rats was found after cocaine treatment (Carouge et al., [@B3]). In the nucleus accumbens of mice, cocaine has been shown to induce *Dnmt3a* and *Dnmt3b* expression, to increase methylation of the promoter region of the *Pp1c* gene, and to decrease the methylation of the *FosB* gene promoter region, thereby increasing MeCP2 binding and decreasing *Pp1*c expression (Anier et al., [@B1]). Cocaine treatment of pregnant dams was reported to induce hypermethylation of specific regions in the promoter of the *PKC*ε gene in the developing fetal heart (Zhang et al., [@B40], [@B41]).

Cocaine has also been shown to alter chromatin remodeling. Both *cFos* and *ΔFosB* expression are activated by cocaine (Graybiel et al., [@B7]; Young et al., [@B39]; McClung and Nestler, [@B21]). This has been shown to occur in parallel with chromatin remodeling. A single injection of cocaine caused chromatin remodeling at the *cFos* promoter and chronic cocaine caused chromatin remodeling at the *ΔFosB* promoter in the striatum (Kumar et al., [@B14]). Acute and chronic cocaine cause hypomethylation of the *FosB* promoter, decreased MeCP2 binding, and upregulated *FosB* expression in the NAc (Anier et al., [@B1]). The micoRNA-212 (miR-212) was recently reported to be upregulated in response to cocaine in the striatum of rats, leading to an amplification of the stimulatory effects of cocaine on CREB signaling (Hollander et al., [@B10]). In the nucleus accumbens of rats, repeated cocaine administration was reported to persistently decrease histone H3 lysine 9 trimethylation, predominately in intergenic repeat regions, possibly contributing to increased gene expression (Maze et al., [@B20]).

The role of 5-hydroxymethylcytosine (5-hmC) in the regulation of gene expression is currently under investigation in a number of studies. For example, 5-hmC has been suggested to play a role in fetal development of the heart, lung, and brain (Kinney et al., [@B11]). The bisulfite conversion technique we used to measure DNA methylation cannot differentiate between 5-methylcytosine (5-mC) and 5-hmC. However, the contribution of 5-hmC is small. 5-mC to 5-hmC has been shown to be approximately 10:1 in murine embryonic stem cells (Tahiliani et al., [@B33]), and in Purkinje or granule cells 0.6 and 0.2%, respectively, of the nucleotide pool is 5-hmC (Kriaucionis and Heintz, [@B12]).

The results of this study indicate that it will be important in future studies to assess changes in gene expression during withdrawal from cocaine self-administration. This would provide further evidence as to the role of DNA methylation in the maturation and myelination. More extensive examination of the time course of DNA methylation changes seen during withdrawal from cocaine self-administration will prove additional valuable information.

There are a number of limitations of this study. The primary limitation was that significant changes in mean DNA methylation did not appear until after 30 days of abstinence. This raises the question of the functional significance of these changes as to our knowledge prior research has not specifically determined effects of age related changes in DNA methylation of *Sox10* on white matter structure. Another limitation is the relatively small number of rodents, which may have contributed to the lack of statistically significant differences in DNA methylation of *Mbp* and *Plp1*. Because of these limitations, the results of this study should be considered preliminary. In spite of these limitations, this is the first study to show differences in DNA methylation in white matter between cocaine self-administration and sham rodents.

In summary, this study provides initial evidence that 30 days of forced abstinence from cocaine self-administration was found to be associated with a differential profile of DNA methylation in a white matter related gene in the corpus callosum relative to sham controls. One potential implication of these findings is that such epigenetic changes contribute to the toxicity of cocaine on myelin structure. Future studies of the relationship between quantity and duration of cocaine use on white matter and gene expression are needed, as are studies on potential pharmacotherapies that could reduce these effects.
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